GlaxoSmithKline (GSK) has appointed its consumer health leader, Emma Walmsley, to take over as CEO when Sir Andrew Witty retires next year. Walmsley has a background in marketing, and joined GSK ...

GlaxoSmithKline’s CEO Emma Walmsley has said the company hopes to get at least six new drug approvals in the next year. In an interview at the JP Morgan Healthcare Conference in San Francisco ...

Emma Walmsley, CEO of GSK, is nearly eight years into her effort to return the British pharma company to growth, and her work is starting to pay off. Much credit goes to Arexvy, GSK’s ...

GSK Plc CEO Emma Walmsley doesn’t want the company’s employees spending any time thinking about the ongoing litigation over its old heartburn drug Zantac, an issue that has weighed on the ...

Emma Walmsley, the Chief Executive Officer of GSK plc (NYSE: GSK), expressed confidence in its respiratory syncytial virus (RSV) vaccine, Arexvy, anticipating sales to surpass £1 billion ($1.26 ...

(Bloomberg) -- When Elliott Investment Management came calling for the ouster of Emma Walmsley ... Philip Hampton, GSK’s ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Zantac may have been a heartburn medicine but it caused one almighty headache for GSK chief executive Emma ...

Early in 2023, British pharma giant GSK launched the world’s first RSV adult vaccine, Arexvy, for those aged 60 years and older. Walmsley, the only woman CEO of a major pharma company ...

Uncertainty around the event and suspected tax changes in the upcoming budget has left many investors in the dark.

GSK is betting on AI to boost innovation for ... but a balanced approach toward regulation is important, CEO Emma Walmsley says. Speaking at the CEO Times Summit in London, Walmsley highlights ...

GSK said it will pay CureVac 400 million euros ... optimally purchase healthcare if he/she has to pay out-of-pocket. Emma Walmsley would like to see Prime Minister Narendra Modi creating a ...

LONDON, U.K. – GSK, and its CEO, Emma Walmsley believe they have been vindicated. Earlier in the decade, GSK, with facilities in Collegeville and Valley Forge, Pa., was under attack by several ...